12:19 AM EDT, 09/11/2026 (MT Newswires) -- Eli Lilly (LLY.SW, LLY.F) plans to direct some of the revenue from its GLP-1 weight-loss and diabetes drugs toward women's health research, Bloomberg News reported Thursday, citing people familiar with the matter. The pharmaceutical giant is accelerating research into underfunded and understudied areas of women's health, including bone health, pregnancy-related disorders, and endometriosis, according to the report. Lilly has hired a reproductive medicine expert, started recruiting scientists focused on osteoporosis and preeclampsia, and expanded some executives' roles to include women's health, the report said. Eli Lilly did not immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.